Flonase ads a top persuader, new marketing study says

Share this article:
GlaxoSmithKline's Flonase was the most successful brand in persuading non-users to consider asking their doctor about the brand (79 percent), according to the results of a new study from the pharma marketing firm Patient Marketing Group (PMG).
PMG's ConsumeRxperience scorecard study is a comprehensive, quantitative study in which DTC initiated relationship marketing programs are rated by the patients they are designed for. DTC ads and follow-up materials are reviewed and  rated by patients and caregivers.
Among the study's key findings were:
•Pfizer's Zyrtec proved to be the most successful in persuading nonusers to consider seeking more disease education (71 percent).
•Zyrtec was also the most effective brand in persuading non-users to consider switching from another allergy medication (18 percent). Brands in some more serious condition categories that were able to persuade at least 10 percent of competitive brand users to consider switching included GSK's antidepressant Wellbutrin XL. Among panel members reviewing materials for a medication they were currently using, 39 percent said they were motivated to be more diligent
in following a doctor's directions.
A total of 1,673 panelists participated in the survey. Promotional materials for 39 brands across 19 conditions were rated for their impact on driving trial-related actions, as well as for content relevance, helpfulness, comprehension, tone and trustworthiness.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.